ELDAPT: Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy

ELDAPT: Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment on the oPtimal Treatment strategy - ELDAPT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54768

Enrollment

288

Registered

2016-02-24

Start date

2016-06-16

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

geriatric Lung cancer

Interventions

All registered patients will have an initial geriatric assessment to assess&nbsp

vulnerability.

Eligibility

Age

65 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with any subtype of NSCLC, primary UICC Stage III, age >= 75 years.

Exclusion criteria

Exclusion criteria: - No NSCLC - Primary UICC stage is not III - younger than 75 years

Design outcomes

Primary

Measure	Time frame
Quality-adjusted survival (QAS)	—

Secondary

Measure	Time frame
• To perform geriatric assessment in stage III NSCLC patients to select patients fit enough to undergo intensified treatment • To identify reliable elements of the geriatric assessment that are predictive for treatment tolerance and QAS in elderly patients with stage III NSCLC • To determine the predictive value of saliva biomarkers with respect to treatment tolerance and QAS in elderly patients with stage III NSCLCTo develop and validate a clinically applicable geriatric screening instrument that enables appropriate treatment stratification in the elderly NSCLC patient • To compare different treatment strategies in fit elderly patients with respect to o Overall survival o Quality adjusted survival • To compare cost-effectiveness of different treatment strategies for fit elderly patients with stage III NSCLC	—

Measure

Time frame

• To perform geriatric assessment in stage III NSCLC patients to select patients fit enough to undergo intensified treatment • To identify reliable elements of the geriatric assessment that are predictive for treatment tolerance and QAS in elderly patients with stage III NSCLC • To determine the predictive value of saliva biomarkers with respect to treatment tolerance and QAS in elderly patients with stage III NSCLCTo develop and validate a clinically applicable geriatric screening instrument that enables appropriate treatment stratification in the elderly NSCLC patient • To compare different treatment strategies in fit elderly patients with respect to o Overall survival o Quality adjusted survival • To compare cost-effectiveness of different treatment strategies for fit elderly patients with stage III NSCLC

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)